NCT02015663 - Tobramycin Inhalation Powder (TIP) Administered Once Daily Continuously Versus TIP Administered BID in 28 Day on / 28 Day Off Cycles | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

January 31, 2014

Primary Completion Date

December 31, 2014

Study Completion Date

December 31, 2014

Conditions

Cystic Fibrosis

Interventions

DRUG

Tobramycin Inhalation Powder

Tobramycin Inhalation Powder 112 mg (four 28-mg capsules) taken via inhaler once or twice a day, depending on study arm

Trial Locations (21)

10595

Novartis Investigative Site, New York

11040

Novartis Investigative Site, New Hyde Park

32207

Novartis Investigative Site, Jacksonville

32504

Novartis Investigative Site, Pensacola

32701

Novartis Investigative Site, Altamonte Springs

32806

Novartis Investigative Site, Orlando

33136

Novartis Investigative Site, Miami

44308

Novartis Investigative Site, Akron

46202

Novartis Investigative Site, Indianapolis

52242

Novartis Investigative Site, Iowa City

60025

Novartis Investigative Site, Glenview

63104

Novartis Investigative Site, St Louis

73112

Novartis Investigative Site, Oklahoma City

78723

Novartis Investigative Site, Austin

84132

Novartis Investigative Site, Salt Lake City

90027

Novartis Investigative Site, Los Angeles

92772

Novartis Investigative Site, Portland

93003

Novartis Investigative Site, Ventura

95819

Novartis Investigative Site, Sacramento

36608-1128

Novartis Investigative Site, Mobile

17033-8050

Novartis Investigative Site, Hershey